Dai­ichi Sankyo sets new highs for As­traZeneca-part­nered can­cer drug En­her­tu

New ap­proved in­di­ca­tions and mas­sive year-over-year sales growth has Dai­ichi Sankyo eye­ing a year-end pop in sales for its As­traZeneca-part­nered can­cer drug En­her­tu.

The Japan­ese phar­ma on Mon­day upped its fore­cast for En­her­tu this year by more than $400 mil­lion, pro­ject­ing it could haul in about $1.3 bil­lion.

The in­crease in En­her­tu sales guid­ance fol­lows a land­mark da­ta drop and stand­ing ova­tion at AS­CO ear­li­er this sum­mer, as well as three la­bel ex­pan­sions as a sec­ond line treat­ment for HER2-pos­i­tive breast can­cer, in HER2-low metasta­t­ic breast can­cer, and as a sec­ond-line treat­ment for HER2-mu­tant metasta­t­ic non-small cell lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER